Pterostilbene for ALS
Also known as: Dimethylresveratrol, trans-3,5-Dimethoxy-4'-hydroxystilbene
Pterostilbene's bioavailable SIRT1 activation may enhance motor neuron resilience through mitochondrial enhancement.
Mechanism of Action
Pterostilbene activates SIRT1/3 in motor neurons, promoting mitochondrial biogenesis and stress resistance. Its anti-inflammatory effects through NF-κB suppression reduce glial-mediated neurotoxicity.
General mechanism: Dimethylated stilbenoid. SIRT1 activator (4x bioavailability of resveratrol), Nrf2 activator, NF-κB inhibitor, epigenetic modulator.
Current Evidence
Preclinical neuroprotection data. Superior bioavailability vs resveratrol for CNS applications. No ALS trials.
Clinical Status: Preclinical. Pharmacokinetic advantage over resveratrol supports investigation.
Safety Profile
Very safe. Well-tolerated at 250mg/day in clinical trials. No significant side effects. Present in blueberries.
Key Research Questions
- Does pterostilbene reach motor neurons at SIRT1-activating concentrations?
- Can pterostilbene provide practical SIRT1-based neuroprotection in ALS?